Scientists have long known that dopamine helps the brain learn from rewards, but a new computational model shows how for ...

A genetic postmortem analysis of the brains of patients with schizophrenia suggests dysfunction of dopamine receptors in the caudate nucleus may cause the disorder. Investigators identified a ...

Schizophrenia risk may reflect two brain pathways with different cortical and subcortical balance. Early language learning ...

How Does Cobenfy Work, and How Is It Different From Other Medicines Used to Treat Schizophrenia? An imbalance of brain chemicals called neurotransmitters may contribute to schizophrenia. Current ...

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults. The FDA approved xanomeline and trospium chloride (Cobenfy) ...

The general consensus among experts is that TRS is a condition in which an individual’s symptoms haven’t responded to two or more antipsychotic medicines given at a therapeutic dose for at least six ...

Please provide your email address to receive an email when new articles are posted on . Cobenfy is the first antipsychotic medication to treat schizophrenia by targeting cholinergic receptors. The ...